Websites
- Valeant and Biovail agree to merge www.biovail.com/english/Investor%20Relations/Latest%20News/default.asp?s=1&state=showrelease&releaseid=1440050
- Celgene to acquire Abraxis BioScience http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1442901&highlight=
- Abraxis BioScience website www.abraxisbio.com
- Midatech and Immunotope form joint venture, Syntara LLC, for the development of immune therapies http://www.midatechgroup.com/media/2010-07-12-Midatech_Immunotope_announcement.pdf
- Diamyd Medical signs agreement for diabetes therapy www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=498942
- Diamyd website, section on GAD platform www.diamyd.com/docs/gadPlatform.aspx?section=science
- Midatech expands collaboration with Monosol Rx to deliver peptides utilizing nanotechnology and PharmFilm® drug delivery technology www.midatechgroup.com/media/Midatech_Monosol_240610_release.pdf
- SurModics signs license agreement with Clinuvel Pharmaceuticals http://phx.corporate-ir.net/phoenix.zhtml?c=80353&p=irol-newsArticle&ID=1445396&highlight=
- Clinuvel website, section on Scenesse®http://clinuvel.com/scenesse
- OctoPlus announces agreement with a major pharmaceutical company on its controlled release technology Link
- OctoPlus announces agreement with a US biotechnology company on its controlled release technology Link
- Webpage and factsheet on Polyactive®www.octoplus.nl/index.cfm/octoplus/drug-delivery/polyactive/index.cfm
- OctoPlus signs drug development contract with The Medicines Company Link
- The Medicines Company website, section: MDCO-216 – product overview www.themedicinescompany.com/products_MDCO216.shtml
- Tekmira awarded up to $140 million US Government contract to develop RNAi therapeutic against Ebola virus www.tekmirapharm.com/News_and_Events/News_Releases/Tekmira07151001.aspx
- Forest and Merz announce FDA approval of Namenda® XR for the treatment of moderate to severe dementia of the Alzheimer‘s type www.frx.com/news/PressRelease.aspx?ID=1440385
- Entry in Drugs@FDA and approved label for Namenda XR capsules www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory
- Merz Pharmceuticals website, partners section www.merz.com/company/merz_pharmaceuticals/partners/
- Entry on Sycrest, EMA website, section pending EC decisions Link
- Entry in Drugs@FDA and approved label for Saphris®www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
- Entry on PecFent, EMA website, section pending EC decisions Link
- Archimedes Pharma receives CHMP positive opinion for PecFent® for the treatment of breakthrough cancer pain www.archimedespharma.com/newseventsNews.html
- Entry in Drugs@FDA and approved label for Butrans™ (buprenorphine) Transdermal System CIII www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
- Purdue Pharma LP receives FDA approval for Butrans™ (buprenorphine) Transdermal System CIII www.purduepharma.com/pressroom/news/20100701.htm
- FDA approves strativa pharmaceuticals‘ Zuplenz® (ondansetron) oral soluble film 2nd July 2010 www.strativapharma.com/index.php?option=com_pr&view=release&releaseid=1444076&Itemid=91
- Entry in Drugs@FDA and approved label for Zuplenz® (ondansetron) oral soluble film www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory
- Pfizer prepares for voluntary withdrawal of US new drug application and for discontinuation of commercial availability of Mylotarg®http://pfizer.mediaroom.com/index.php?s=5149&item=4960
- Affymax and Takeda announce Phase 3 trials meet primary endpoints for investigational drug, Hematide™/peginesatide, to treat anemia in chronic renal failure with some differences noted in secondary analyses www.investors.affymax.com/releasedetail.cfm?ReleaseID=481068
- Affymax® receives $30 million milestone payments for database lock of Phase 3 clinical trials for Hematide™/peginesatide www.investors.affymax.com/releasedetail.cfm?ReleaseID=481581
- New clinical study shows patients with Type 2 diabetes may be able to tolerate higher doses of Metformin using Glumetza®http://investor.depomedinc.com/phoenix.zhtml?c=97276&p=irol-newsArticle&ID=1442334&highlight=
- Depomed website, technology section www.depomed.com/view.cfm/32/Our-Technology
- Small, smart, stealth nanoparticles seek-and-destroy metastatic cancers, as epeius biotechnologies advances its intellectual property estate with additional US patents www.epeiusbiotech.com/small_smart_press.asp
- Epeius Biotechologies website, oncology section www.epeiusbiotech.com/oncology-overview.asp
- Aphios awarded United States patent for polymer drug delivery nanotechnology platform www.aphios.com/Press/Aphios_PR_USPatent_PolymerNanospheres_062210.pdf